PepGen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. The company utilizes its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, which employs cell-penetrating peptides to improve the tissue penetration, cellular uptake, and nuclear delivery of conjugated oligonucleotide therapeutics. Its lead product candidate, PGN-EDODM1, is designed to treat myotonic dystrophy type 1 (DM1) by binding to pathogenic CUG repeat expansions in DMPK mRNA to correct downstream mis-splicing events. Clinical trials for PGN-EDODM1 are conducted in the United States, Canada, the United Kingdom, South Korea, Australia, and New Zealand. The company focuses on addressing the underlying genetic causes of neuromuscular disorders and intends to expand the application of its EDO technology to additional severe diseases with significant unmet need.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage pepgen.com
Sector Healthcare IR page investors.pepgen.com/news-events/news-releases
Tags
oligonucleotide therapeutics, neuromuscular diseases, myotonic dystrophy, cell-penetrating peptides, rna splicing, gene therapy, clinical-stage, drug delivery, PGN-EDODM1, EDO platform, FREEDOM-DM1, FREEDOM2-DM1, FREEDOM-OLE
Press page —

Metrics

Valuation  
Market cap $ 346.306M
Market cap (USD) $ 346.306M
P/E -6.41
PEG —
P/BV 3.36
P/S —
P/OCF -5.48
P/FCF -5.47
Dividend yield —
Turnover / mcap —
Returns  
ROE -67.4%
ROI -89.0%
ROIC -69.7%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 18
Quality score -53.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Assets 173.907M 150.883M 143.052M 217.44M 143.641M
Net profit -89.655M -89.981M -78.626M -69.104M -27.281M
Free cash flow -81.899M -82.869M -71.596M -63.02M -23.099M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 6.51 3.79 6.8 13.37 —
Price performance 12m 0.72 -0.44 -0.49 — —

Filed figures

Figure Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 24.5M 20.1M 18.7M 17M
Cash and deposits (USD) 133M 182M 80.8M 49.4M 60.5M
Right-of-use assets (USD) — 26.5M 23.6M 21.4M 19.1M
Cash flow detail
Operating cash flow (USD) -22.6M -59.3M -69M -82.4M -81.6M
Purchases of property, plant and equipment (USD) -500,000 -3.76M -2.6M -497,000 -264,000
Income taxes paid (cash effect) (USD) — — -2.7M -71,000 -82,000
Share-based compensation (USD) 1.53M 4.76M 7.05M 11.5M 10.6M
Free cash flow (OCF - PPE - intangibles) (USD) -23.1M -63M -71.6M -82.9M -81.9M
Income detail
Research and development expense (USD) 19M 54.1M 68.1M 76.5M 71M
Total comprehensive income (USD) -27.3M -69.2M -78.5M -90M -89.7M
Comprehensive income to owners (USD) -27.3M -69.2M -78.5M -90M -89.7M
Reported Mar 23, 2023 Mar 23, 2023 Mar 6, 2024 Feb 24, 2025 Mar 4, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

BOSTON— November 10, 2026 — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases, today announced the launch of a public offering of $125.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, PepGen intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock the securities to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions. All of the securities to be sold in the proposed offering are being offered by PepGen. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

PepGen currently intends to use the net proceeds from this offering to fund ongoing clinical development of its product candidate, as well as for working capital and other general corporate purposes.

PepGen Reports Third Quarter 2026 Financial Results Bull 6 Bear 0 Clinical/regulatory

and Recent Corporate Highlights

–Positive FREEDOM2-DM1 10 mg/kg cohort results demonstrated highest reported splicing correction and improvements across multiple functional measures –

– 12.5 mg/kg FREEDOM2-DM1 cohort fully enrolled, with participants having received up to three doses; results expected in 1H 2027 –

– FREEDOM-OLE 10 mg/kg safety and 5 mg/kg clinical data expected in January 2027 –

– Well-funded with $104.8M of cash as of September 30, 2026, sufficient to fund operations into 2028 –

BOSTON— November 10, 2026-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2026. PepGen also released today positive topline results from the 10 mg/kg multiple ascending dose cohort of the ongoing Phase 2 FREEDOM2-DM1 trial (NCT06667453) evaluating PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1), a rare, progressive, and multisystemic genetic disease.

August 6, 2026

PDF Version

– DSMB also recommended dose escalation in FREEDOM-OLE from 5 mg/kg to 10 mg/kg –

BOSTON--(BUSINESS WIRE)--Aug. 6, 2026-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that an independent Data and Safety Monitoring Board (DSMB) has recommended advancing the ongoing Phase 2 FREEDOM2-DM1 study evaluating PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) into the third and highest multiple ascending dose (MAD) cohort of 12.5 mg/kg, with no recommended changes to the study protocol. The DSMB also recommended dose escalation in the open-label extension (OLE) study from 5 mg/kg to 10 mg/kg. Notably, 6 of 8 participants from the 5 mg/kg FREEDOM2 cohort have elected to enroll in the OLE, bringing total OLE enrollment to 16 participants. The recommendation followed a review of available safety data from the fully enrolled 10 mg/kg MAD cohort and the OLE study.

PGN-EDODM1 remains generally well-tolerated, with no serious adverse events or dose-limiting toxicities reported in FREEDOM2 or the OLE to date. Repeat dosing at both the 5 mg/kg and 10 mg/kg dose levels shows no evidence of cumulative toxicity, and no treatment discontinuations were reported in FREEDOM2 or the OLE.

“The DSMB's recommendation to advance FREEDOM2 into the highest planned dose level in the study and escalate dosing in the OLE supports the encouraging safety profile of PGN-EDODM1 following multiple months of treatment,” said James McArthur, PhD, President and Chief Executive Officer of PepGen. “In the FREEDOM2 study, 7 of 8 participants in the 10 mg/kg cohort have now completed dosing. We look forward to reporting additional safety, splicing and functional data from FREEDOM2 as we continue to evaluate the potential of PGN-EDODM1 to address the root cause of disease across multiple organ systems.”

The Company expects to report results from the fully enrolled 10 mg/kg FREEDOM2 cohort in November. Results from the 12.5 mg/kg cohort are expected in the first half of 2027, at which time PepGen plans to engage with regulators in an end of Phase 2 meeting to discuss plans for the registrational program. The Company also expects to provide an update from the OLE study by early January.

About PGN-EDODM1

PGN-EDODM1, PepGen's investigational candidate in development for the treatment of DM1, utilizes the Company's proprietary EDO technology to deliver a therapeutic oligonucleotide that is designed to restore the normal splicing function of MBNL1, a key RNA splicing protein. PGN-EDODM1 addresses the deleterious effects of cytosine-uracil-guanine (CUG) repeat expansion in the dystrophia myotonica protein kinase (DMPK) transcripts which sequester MBNL1, by binding to the pathogenic CUG trinucleotide repeat expansion present in the DMPK transcripts and disrupting the binding between the CUG repeat expansion and MBNL1. PepGen believes this innovative therapeutic approach may have considerable advantages over oligonucleotide modalities that rely on knockdown or degradation of the DMPK transcripts as it will allow the DMPK transcripts to continue to perform their normal function within the cell, while also liberating MBNL1 to correct downstream mis-splicing events. The U.S. Food and Drug Administration has granted PGN-EDODM1 both Orphan Drug and Fast Track Designations for the treatment of patients with DM1. The European Medicines Agency (EMA) has recently granted Orphan Designation for PGN-EDODM1.

About PepGen

PepGen Inc. is a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.

Prompts

PepGen Inc. (ticker PEPG), listed in United States.

ETFs Holding PepGen Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.01% 55,293 $ 231.678K Nov 16, 2026
DFSU 0.00% 11,671 $ 58.822K Nov 12, 2026
DXUV 0.00% 20,181 $ 101.712K Nov 12, 2026
DFAU 0.00% 10,468 $ 52.759K Nov 12, 2026
DFAS 0.00% 22,178 $ 111.777K Nov 12, 2026
DCOR 0.00% 6,228 $ 31.389K Nov 12, 2026